Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2008
11/19/2008EP1991260A1 Immune system stimulant and process of manufacturing the same
11/19/2008EP1991259A2 Viral display vehicles for treating multiple sclerosis
11/19/2008EP1991058A1 Attenuated francisella and methods of use
11/19/2008EP1638601B1 Carrier proteins for vaccines
11/19/2008EP1545607B1 Allergy vaccines
11/19/2008EP1513553B1 Methods and materials for treating and diagnosing kallikrein-6 related inflammatory conditions
11/19/2008EP1503781B1 Treatment for reduction of body weight gain
11/19/2008EP1453539B1 Immunotherapeutic methods and systems
11/19/2008EP1432990B1 Diabetic model
11/19/2008EP1428870B1 Reduction in the virulence of mycobacterium tuberculosis and protection against tuberculosis by means of phop gene inactivation
11/19/2008EP1428537B1 Stabilized preparations containing antibody
11/19/2008EP1373510B1 Mutant allergens
11/19/2008EP1358213B1 Humanized antibodies that recognize beta amyloid peptide
11/19/2008EP1206555B1 Fv antibody construct comprising binding sites for a cd16 receptor and a cd30 surface protein
11/19/2008EP1123711B1 Attenuated toxins as adjuvants
11/19/2008EP1112084B1 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
11/19/2008EP0925073B1 Staphylococcus aureus antigen
11/19/2008EP0888120B1 Immunogenic hla binding peptide and its uses to treat hiv infection
11/19/2008CN101309933A Toxin conjugated eph receptor antibodies
11/19/2008CN101309931A Vaccines comprising truncated HBC core protein plus saponin-based adjuvants
11/19/2008CN101309705A Preventive or therapeutic agent and method for immune disease
11/19/2008CN101309704A Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
11/19/2008CN101309703A 抗cd3抗体组合物 Anti-cd3 antibody compositions
11/19/2008CN101309702A Methods and compositions for treating female infertility using clomiphene
11/19/2008CN101309701A Vaccines and methods to treat canine influenza
11/19/2008CN101309700A Therapeutic use of outer shigella protein f (ospf)
11/19/2008CN101309699A Stabilized virus-like particles and epitope display systems
11/19/2008CN101309681A Combinations comprising dmxaa for the treatment of cancer
11/19/2008CN101307317A Method for preparing rabies virus antigen
11/19/2008CN101307314A Method for constructing and preparing vaccine against type 2 diabetes mellitus
11/19/2008CN101307312A Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof
11/19/2008CN101307305A Low virulent strain of porcine reproductive and respiratory syndrome virus, immunogenicity immunogenicity material and vaccine
11/19/2008CN101307304A Anti-human ovarian carcinoma anti-anti-idiotype antibody hybridoma cell line, and monoclonal antibody and application thereof
11/19/2008CN101307110A Preparation method of enhancing peptide fragment immunocompetence and use
11/19/2008CN101307109A Mouse-anti-human T lymphocyte CD3 surface antigen monoclonal antibodies, method for preparing same and use
11/19/2008CN101307107A Protein tau
11/19/2008CN101307098A Preparation method of enhancing peptide fragment immunocompetence and use
11/19/2008CN101307097A Preparation method of enhancing peptide fragment immunocompetence and use
11/19/2008CN101307096A Preparation method of enhancing peptide fragment immunocompetence and use
11/19/2008CN101307095A T-cell epitope peptide
11/19/2008CN101306200A Preparation method of hepatitis b human immunoglobulin for intravenous injection
11/19/2008CN101306199A Method for producing and purifying hepatitis a inactivated vaccine
11/19/2008CN101306198A NR2B recombinant adenovirus vaccine
11/19/2008CN100434519C Curing and preventing method
11/19/2008CN100434441C Inhibition of viral infection using monovalent antigen-binding proteins
11/19/2008CN100434440C Antibodies directed to tumor necrosis factor and uses thereof
11/19/2008CN100434439C Genes and polypeptides relating to chronic myeloid leukemia
11/19/2008CN100434119C Method for producing yelk antibody liquid in high immunity
11/19/2008CN100434118C Application of cysteamine and its derivative in preparing medicine for raising potency of vaccine antibody
11/18/2008US7452982 An immunogenic complex characterised in that an enzyme is integrated into an immunostimulating complex (ISCOM) containing a glycoside, a lipid and an antigen
11/18/2008US7452979 Cancerous disease modifying antibodies
11/18/2008US7452978 Cancerous disease modifying antibodies
11/18/2008US7452976 Immunoglobulin specific to kinase insert domain-containing receptor (KDR) for use in treatment and prevention of inflammation, psoriasis, rheumatoid arthritis and tumor growth; immunotherapy
11/18/2008US7452971 Compositions and methods for modifying toxic effects of proteinaceous compounds
11/18/2008US7452963 From 7 to 50 amino acids comprising: (1) a lysine residue six to ten residues from a second lysine residue; (2) a histidine residue; and (3) at least 6% lysine residues
11/18/2008US7452874 Thrombopoietin mimetics
11/18/2008US7452857 Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
11/18/2008US7452723 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
11/18/2008US7452717 Carboxylesterase; antitumor agents; drug screening; bioassay
11/18/2008US7452715 expression of the lipidated form of the peptidoglycan-associated protein (PAL) of gram-negative bacteria is achieved through the use of a plasmid containing a tightly regulated promoter; bacterial host cell transformed, transduced or transfected with the plasmid
11/18/2008US7452697 Chromatographic method and system for purifying a botulinum toxin
11/18/2008US7452696 Recombinant plasmid and method for expressing hepatitis B viral antigens and virions in vivo
11/18/2008US7452544 Bacteriocins and novel bacterial strains
11/18/2008US7452542 Live attenuated coronavirus vaccines
11/18/2008US7452541 Hapten-carrier conjugates and uses thereof
11/18/2008US7452540 Enhanced immunization and suppression of oral tolerance
11/18/2008US7452539 Performing polypeptide exposure to urea in the presence of a glycine containing solution to deactivate viral contaminants
11/18/2008US7452538 Death domain containing receptor 4 antibodies and methods
11/18/2008US7452537 Modulation of P-cadherin mediated adhesion and intracellular signaling is expected to result in decreased proliferation and survival of tumor cells in vivo
11/18/2008US7452536 Inhibiting OX-2 (also called CD200) gene expression to treat a tumor that is associated with increased CD200 expression; leukemia; phage display screening for antigens; monoclonal antibodies; fusion proteins; use of OX-2 preventing graft rejection, autoimmune disease, and in inducing tumor cell growth
11/18/2008US7452535 Methods of treatment using CTLA-4 antibodies
11/18/2008US7452534 low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life); chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences
11/18/2008US7452530 Administering a blocking agent of tumor necrosis factors or receptors; treatment of Sin Nombre (SNV), Ebola, Marburg, Lassa, and Dengue viral disease
11/18/2008CA2588106A1 Single-domain antibodies and heavy chain antibody against egfr and uses thereof
11/18/2008CA2440399C Epitope testing using hla
11/18/2008CA2437201C Methods and compositions useful for stimulating an immune response
11/18/2008CA2417500C Erbb-2 selective small molecule kinase inhibitors
11/18/2008CA2344166C Compositions of .beta.-glucans and specific igiv
11/18/2008CA2288234C Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with porphyromonas gingivalis
11/18/2008CA2210491C Antagonists of interleukin-15
11/18/2008CA2186851C Use of mycobacteria for the treatment of tumours
11/18/2008CA2172376C Antibodies to cd40
11/18/2008CA2156495C Methods for inhibiting hiv associated disease using monoclonal antibodies directed against anti-self cytotoxic t-cells
11/18/2008CA2138594C Process for preparing clear sera which are stable over a long period
11/18/2008CA2136230C Clostridium perfringens vaccines
11/18/2008CA1341585C Recombinant retroviruses
11/13/2008WO2008138017A2 Methods and compositions for modifying t cell immune responses and inflammation
11/13/2008WO2008137981A1 Human parainfluenza viruses having separated p and c genes
11/13/2008WO2008137915A2 Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
11/13/2008WO2008137901A2 Methods for treating and preventing gi syndrome and graft versus host disease
11/13/2008WO2008137838A2 Interferon alpha-induced pharmacodynamic markers
11/13/2008WO2008137835A2 Auto-antibody markers of autoimmune disease
11/13/2008WO2008137747A1 Nanoemulsion therapeutic compositions and methods of using the same
11/13/2008WO2008137705A1 Prevention of cancers by immunization
11/13/2008WO2008137600A1 Methods for measuring platelet reactivity of individuals treated with drug eluting stents
11/13/2008WO2008137567A1 Caspase inhibitors in the treatment of infection-associated preterm delivery
11/13/2008WO2008137552A2 Anti-rage antibodies and methods of use thereof
11/13/2008WO2008137500A2 Immunosuppression with antibody against itm2a
11/13/2008WO2008137446A1 Methods and compositions for the treatment of respiratory disease
11/13/2008WO2008137163A1 Two-component genome flavivirus and uses thereof
1 ... 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 ... 1823